Evidence map›Paper›PMID 29976767›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2018

MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium.

Virginie Joris, Elvira Leon Gomez, Lisa Menchi, Irina Lobysheva, Vittoria Di Mauro, Hrag Esfahani, Gianluigi Condorelli, Jean-Luc Balligand, Daniele Catalucci, Chantal Dessy

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. RNA Therapeutics in Heart Failure.Journal of cardiovascular translational research · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Vascular Ageing: Mechanisms, Risk Factors, and Treatment Strategies.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Virginie JorisFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
Elvira Leon GomezFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
Lisa MenchiFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
Irina Lobysheva
Vittoria Di MauroHumanitas University, Rozzano (Milan), Italy (V.D.M., G.C.).
Hrag EsfahaniFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
Gianluigi CondorelliHumanitas University, Rozzano (Milan), Italy (V.D.M., G.C.).
Jean-Luc BalligandFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
Daniele CatalucciHumanitas#8232, Clinical and Research Center, Rozzano (Milan), Italy (V.D.M., G.C., D.C.).
Chantal DessyFrom the Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium (V.J., E.L.G., L.M., H.E., J.-L.B., C.D.).
UCLouvain · BEHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective- Members of the microRNA (miR)-199a family, namely miR-199a-5p and miR-199a-3p, have been recently identified as potential regulators of cardiac homeostasis. Also, upregulation of miR-199a expression in cardiomyocytes was reported to influence endothelial cells. Whether miR-199a is expressed by endothelial cells and, if so, whether it directly regulates endothelial function remains unknown. We investigate the implication of miR-199a products on endothelial function by focusing on the NOS (nitric oxide synthase)/NO pathway. Approach and Results- Bovine aortic endothelial cells were transfected with specific miRNA inhibitors (locked-nucleic acids), and potential molecular targets identified with prediction algorithms were evaluated by Western blot or immunofluorescence. Ex vivo experiments were performed with mice treated with antagomiRs targeting miR-199a-3p or -5p. Isolated vessels and blood were used for electron paramagnetic resonance or myograph experiments. eNOS (endothelial NO synthase) activity (through phosphorylations Ser1177/Thr495) is increased by miR-199a-3p/-5p inhibition through an upregulation of the PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B) and calcineurin pathways. SOD1 (superoxide dismutase 1) and PRDX1 (peroxiredoxin 1) upregulation was also observed in locked-nucleic acid-treated cells. Moreover, miR-199a-5p controls angiogenesis and VEGFA (vascular endothelial growth factor A) production and upregulation of NO-dependent relaxation were observed in vessels from antagomiR-treated mice. This was correlated with increased circulated hemoglobin-NO levels and decreased superoxide production. Angiotensin infusion for 2 weeks also revealed an upregulation of miR-199a-3p/-5p in vascular tissues. Conclusions- Our study reveals that miR-199a-3p and miR-199a-5p participate in a redundant network of regulation of the NOS/NO pathway in the endothelium. We highlighted that inhibition of miR-199a-3p and -5p independently increases NO bioavailability by promoting eNOS activity and reducing its degradation, thereby supporting VEGF-induced endothelial tubulogenesis and modulating vessel contractile tone.

Indexed as

Neovascularization, PhysiologicVasodilationAngiogenesis InhibitorsAnimalsAntagomirsCattleCells, CulturedDisease Models, AnimalEndothelial CellsEndothelium, VascularEnzyme StabilityGene Expression Regulation, NeoplasticHypertensionMaleMice, Inbred C57BLMicroRNAsAngiogenesis InhibitorsAntagomirslocked nucleic acidMicroRNAsMirn199 microRNA, mouseNitric OxideNitric Oxide Synthase Type IIINos3 protein, mouseOligonucleotidesPeroxiredoxinsPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPrdx1 protein, mouseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSod1 protein, mouseSuperoxide Dismutase-1Vascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseendothelial cellsendothelial dysfunctionmicroRNAnitric oxideoxidative stress

Identifiers

PMID29976767
OpenAlexW2846639189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.